Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $37.30 to a high of $39.64. Yesterday, the shares fell 8.0%, which took the trading range below the 3-day low of $40.21 on volume of 993,000 …
Myriad Genetics, Inc. MYGN presented encouraging data from a study to evaluate ... Over the past year, the company’s share price has outperformed the broader industry. The stock has gained 90.1%, in contrast to the broader industry’s …
Inc. MYGN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 83.9% over a year. …
Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the …
Inc. MYGN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. PetMed has a long-term expected earnings growth rate of 10%. The stock has surged roughly 77.9% over a year. …
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site …
What’s next? Myriad’s stock was in some trouble until recently. A monthly stock chart shows that MYGN was in a bear market for pretty much all of 2016. It finally started to bottom late in 2016, and completed its bottom in May of 2017. It’s …
Myriad Genetics, Inc. MYGN was a big mover last session, as its shares rose over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for …